1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc.

IMDX
Insight Molecular Diagnostics Inc.US flagNASDAQ Capital Market
6.63
USD
+0.60
- -
177.82MMarket Cap

Total Valuation

Insight Molecular Diagnostics Inc. carries a market capitalization of 177.82M, placing it among publicly traded companies globally. Its enterprise value stands at 81.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap177.82M
Enterprise Value81.99M

Share Statistics

Insight Molecular Diagnostics Inc. currently has 32.29M shares outstanding.

Shares Outstanding32.29M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 54.96, and the price-to-book ratio stands at -9.95.

PE RatioN/A
PS Ratio54.96
PB Ratio-9.95
P/TBV Ratio-10.02
P/FCF Ratio-5.23
P/OCF Ratio-4.47

Enterprise Valuation

EV / Sales42.07
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Insight Molecular Diagnostics Inc. maintains a current ratio of 2.54, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -28.71, indicating conservative leverage, while an interest coverage ratio of -316.36 demonstrates limited ability to service its debt obligations.

Current Ratio2.54
Quick Ratio2.36
Debt / Equity-28.71
Debt / EBITDA-0.09
Interest Coverage-316.36

Financial Efficiency

Return on Equity (ROE)-535.64
Return on Assets (ROA)-94.93
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.26

Stock Price Statistics

Insight Molecular Diagnostics Inc.'s stock has gained approximately 126.10922% over the past 52 weeks. The 50-day moving average sits at 4.55, while the 200-day moving average is 5.05.

Beta (5Y)N/A
52-Week Price Change126.10922%
50-Day Moving Average4.55
200-Day Moving Average5.05
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Insight Molecular Diagnostics Inc. generated 1.95M in revenue and converted that into -47.84M in net income, yielding earnings per share of -1.46. EBITDA reached -32.58M, while operating income came in at -34.92M.

Revenue1.95M
Gross Profit1.00M
Operating Income-34.92M
Pretax Income-47.84M
Net Income-47.84M
EBITDA-32.58M
EBIT-34.92M
Earnings Per Share (EPS)-1.46

Balance Sheet

Insight Molecular Diagnostics Inc. holds 28.20M in cash and equivalents against 3.07M in total debt, resulting in a net debt position of -28.20M. Total book value stands at -10.76M, with working capital of 18.51M providing operational flexibility.

Cash & Cash Equivalents28.20M
Total Debt3.07M
Net Debt-28.20M
Equity (Book Value)-10.76M
Book Value Per Share-0.33
Working Capital18.51M

Cash Flow

Insight Molecular Diagnostics Inc. produced -23.98M in operating cash flow over the past twelve months. After subtracting -3.49M in capital expenditures, free cash flow totaled -27.47M - equivalent to -0.84 per share.

Operating Cash Flow-23.98M
Capital Expenditures-3.49M
Free Cash Flow-27.47M
FCF Per Share-0.84

Margins

Insight Molecular Diagnostics Inc. operates with a gross margin of 51.31, reflecting its pricing power and cost economics. The operating margin of -1,791.79 and net profit margin of -2,454.64 provide insight into operational efficiency.

Gross Margin51.31
Operating Margin-1,791.79
Pretax Margin-2,454.64
Profit Margin-2,454.64
EBITDA Margin-1,671.88

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-22.60
FCF Yield-19.13

Stock Splits

Insight Molecular Diagnostics Inc.'s most recent stock split took place on July 25, 2023 with a 20:1 split ratio.

Last Split Date7/25/2023
Split Ratio20:1

Scores

Insight Molecular Diagnostics Inc. posts an Altman Z-Score of -15.02, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-15.02